928830-73-3 Usage
Description
1-(5-Fluoro-2,4-dinitrophenyl)-4-methylpiperazine is a chemical compound that is a derivative of piperazine. It contains a 5-fluoro-2,4-dinitrophenyl group and a 4-methylpiperazine group. 1-(5-FLUORO-2,4-DINITROPHENYL)-4-METHYLPIPERAZINE is known for its ability to act as a nucleophile in chemical reactions, making it a valuable building block in the production of various chemicals. Its unique structure and reactivity also make it a useful tool for studying and understanding chemical reactions and mechanisms.
Uses
Used in Pharmaceutical Industry:
1-(5-Fluoro-2,4-dinitrophenyl)-4-methylpiperazine is used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. Its nucleophilic properties and unique structure contribute to the development of new drugs and therapeutic agents.
Used in Chemical Research:
1-(5-Fluoro-2,4-dinitrophenyl)-4-methylpiperazine is used as a research tool for studying and understanding chemical reactions and mechanisms. Its reactivity and structure provide insights into various chemical processes and can help in the design of new chemical compounds and materials.
Check Digit Verification of cas no
The CAS Registry Mumber 928830-73-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,8,8,3 and 0 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 928830-73:
(8*9)+(7*2)+(6*8)+(5*8)+(4*3)+(3*0)+(2*7)+(1*3)=203
203 % 10 = 3
So 928830-73-3 is a valid CAS Registry Number.
InChI:InChI=1/C12H15FN4O3.H2O/c1-14-3-5-16(6-4-14)12-7-9(13)10(17(19)20)8-11(12)15(2)18;/h7-8H,2-6H2,1H3;1H2
928830-73-3Relevant articles and documents
Benzimidazole-based compounds kill Mycobacterium tuberculosis
Gong, Yaling,Somersan Karakaya, Selin,Guo, Xiaoyong,Zheng, Purong,Gold, Ben,Ma, Yao,Little, David,Roberts, Julia,Warrier, Thulasi,Jiang, Xiuju,Pingle, Maneesh,Nathan, Carl F.,Liu, Gang
, p. 336 - 353 (2014/03/21)
Tuberculosis remains one of the deadliest infectious diseases, killing 1.4 million people annually and showing a rapid increase in cases resistant to multiple drugs. New antibiotics against tuberculosis are urgently needed. Here we describe the design, sy